4
项与 Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech) 相关的临床试验Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B Cell Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B Cell Lymphoma
Study Evaluating Safety and Efficacy of CD19 and CD22 Targeted Prime CAR-T Cell in Patients With Relapsed/Refractory B-ALL
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted prime CAR-T cells therapy for patients with relapsed/refractory B -ALL
CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma
This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.
100 项与 Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech) 相关的临床结果
100 项与 Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech) 相关的转化医学
100 项与 Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech) 相关的专利(医药)
100 项与 Anti-CD19/CD22 CAR-T cell therapy (Chongqing Precision Biotech) 相关的药物交易